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Abstract
Background
Chronic widespread musculoskeletal pain (CWP) is the cardinal symptom of fibromyalgia
and affects about 12% of the general population. Familial aggregation of CWP has been
repeatedly demonstrated with estimated heritabilities of around 50%, indicating a genetic
susceptibility. The objective of the study was to explore genome-wide disease-differentially
methylated positions (DMPs) for chronic widespread pain (CWP) in a sample of unrelated
individuals and a subsample of discordant monozygotic (MZ) twins.
Methodology/Principle Findings
A total of N = 281 twin individuals from the TwinsUK registry, including N = 33 MZ twins dis-
cordant for self-reported CWP, were part of the discovery sample. The replication sample
included 729 men and 756 women from a subsample of the KORA S4 survey–an indepen-
dent population-based cohort from Southern Germany. Epigenome-wide analysis of DNA
methylation was conducted using the Illumina Infinium HumanMethylation 450 DNA Bead-
Chip in both the discovery and replication sample. Of our 40 main loci that were carried for-
ward for replication, three CPGs reached significant p-values in the replication sample,
including malate dehydrogenase 2 (MDH2; p-value 0.017), tetranectin (CLEC3B; p-value
0.039), and heat shock protein beta-6 (HSPB6; p-value 0.016). The associations between
the collagen type I, alpha 2 chain (COL1A2) and monoamine oxidase B (MAOB) observed
in the discovery sample–both of which have been previously reported to be biological candi-
dates for pain–could not be replicated.
PLOS ONE | DOI:10.1371/journal.pone.0165548 November 10, 2016 1 / 13
a11111
OPENACCESS
Citation: Burri A, Marinova Z, Robinson MD,
Ku¨hnel B, Waldenberger M, Wahl S, et al. (2016)
Are Epigenetic Factors Implicated in Chronic
Widespread Pain? PLoS ONE 11(11): e0165548.
doi:10.1371/journal.pone.0165548
Editor: Michael Costigan, Boston Children’s
Hospital and Harvard Medical School, UNITED
STATES
Received: March 6, 2016
Accepted: October 13, 2016
Published: November 10, 2016
Copyright: © 2016 Burri et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The data are not
publicly available, since the authors have an ethical
duty to the TwinsUK and KORA volunteers to
protect their identity. Data are available from the
UK Twins Research Executive Committee (TREC, at
King’s College London) and data requests may be
sent to victoria.vazquez@kcl.ac.uk.
Funding: The study was supported by Arthritis
Research UK (grant 20682). TwinsUK: the cohort
was supported by the Wellcome Trust; European
Community’s Seventh Framework Programme
(FP7/2007-2013). The study also receives support
Conclusion/Significance
Our results may serve as a starting point to encourage further investigation in large and
independent population-based cohorts of DNA methylation and other epigenetic changes
as possible disease mechanisms in CWP. Ultimately, understanding the key mechanisms
underlying CWP may lead to new treatments and inform clinical practice.
Introduction
Chronic widespread musculoskeletal pain (CWP) is the cardinal symptom of fibromyalgia
(FM), emphasizing axial pain as a constant feature, as well as the presence of pain in the upper
and lower quadrants of abdomen, and the right and left sides of the body [1]. Musculoskeletal
pain affects about 12% of the general population, with the proportion of women being gener-
ally twice as high compared to men [2]. CWP is a diagnosis that challenges the social and cul-
tural boundaries of current perception of illness and health in the Western world and the lack
of a biomedical diagnosis denies the sufferer’s legitimacy of the "sick role". CWP is not only a
huge burden for sufferers, but also difficult to treat and costly for society overall. Despite recent
research efforts, the CWP etiology and mechanisms remain unclear, with evidence from a
range of epidemiologic studies suggesting an interplay of socio- demographic, psychosocial,
affective, physiological, as well as genetic factors [3–8].
Familial aggregation of CWP has been repeatedly demonstrated with estimated heritabili-
ties of around 50% [3,5]. Although several studies have been performed to search for biomark-
ers, they have been mostly underpowered, restricted by the heterogeneity of the phenotype,
constrained by study design, and consequently remain unreplicated [9]. Nevertheless, several
biochemical factors (e.g., androgens) [10] and candidate genes—in particular genes involved
in neurotransmission and part of the dopaminergic and serotonergic pathways and/or impor-
tant for the hypothalamic-pituitary-adrenal (HPA) axis—have been suggested as related to eti-
ology of the condition [9]. Furthermore, the most recent and so far largest genome-wide
association (GWAS) meta-analysis has found evidence for chaperonin containing TCP1 sub-
unit 5 (CCT5) and family with sequence similarity 173 member B (FAM173B) as promising
candidates in pain regulation of CWP [7].
Despite evidence of a genetic basis, environmental components seem to be equally impor-
tant in the pathogenesis of CWP, suggesting a possible role of gene-environment interaction
in the development of the condition [3,5]. Thus, exploration of the DNA epigenetic patterns
that regulate gene expression profiles may offer a new model to understand the dynamic inter-
actions between stochastic, environmental, genetic and epigenetic factors that influence an
individual‘s musculoskeletal pain perception and expression. As such, specific epigenetic
markers may provide quantifiable measures of lifetime environmental exposures and thus
could offer a new biological framework for the cognitive-behavioral causes underlying CWP.
Recent research attempts implementing this methodology have provided promising novel
insights into the etiological mechanisms underlying CWP/FM. In a genome-wide methylation
study, Menzies and colleagues were able to observe significant differences in methylation pat-
terns between 10 women with FM and 42 healthy controls, with the differentially methylated
sites including brain derived neurotrophic factor (BDNF), N(alpha)-acetyltransferase 60, NatF
catalytic subunit (NAT15), or protein kinase C alpha (PRKCA)–all of which show biological
relevance to FM [11]. While these initial results are promising, they remain unreplicated,
restricted to a small sample and therefore extremely underpowered. Furthermore, and to the
best of our knowledge, no studies have looked at epigenetic markers for CWP.
Epigenetics of CWP
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Given previous support for a role of methylation changes in FM-related pain, we conducted
a detailed epigenome-wide analysis study (EWAS) of CWP-differentially methylated positions
(DMPs) in peripheral blood DNA using the Illumina Infinium HumanMethylation 450 DNA
BeadChip. Analyses were conducted on a sample of N = 281 unrelated individuals with avail-
able CWP data and in a subsample of 66 monozygotic (MZ) twins (33 twin pairs) discordant
for CWP from the UK. Epigenetic studies of disease-discordant MZ twins, who are completely
matched for genetics, age, sex, cohort effects, maternal influences and—to a certain extent—
common environment, are considerably more powerful in detecting disease-related epigenetic
differences and therefore the ideal for similar studies [12]. The 20 most significant loci from
both the complete sample and the twin pairs subsample were carried forward for replication in
an iindependent sample of 729 men and 756 women.
Materials and Methods
Participants and Study Design
The discovery sample was drawn from the TwinsUK registry, which has been shown to be repre-
sentative and comparable to the general population in terms of behavior, lifestyle factors and dis-
eases [13]. For detailed information on the twin cohort, see [14,15]. Zygosity was confirmed by
genotyping [16]. Collection of CWP phenotypes and genetic/epigenetic information (from blood
samples) was carried out during clinical visits and via postal questionnaires. The twin subjects
were unaware of the research interests of the present study. In the end, matching phenotype and
epigenome-wide data was available for a total of N = 281 subjects. All twins provided written in-
formed consent and the study was approved by St. Thomas’ Hospital Research Ethics Committee.
The independent replication sample included 729 men and 756 women from a subsample
of the KORA S4 survey, which was performed between 1999 and 2000. The KORA study
includes a series of independent population-based surveys (S1-S4) recruiting participants from
the region of Augsburg in Southern Germany and was initially set up as a cross-sectional sur-
vey to explore development and course of chronic diseases in a sample of adult individuals
[17]. The KORA study was conducted according to the principles expressed in the Declaration
of Helsinki. Written informed consent had been given by each participant. The study was
reviewed and approved by the local ethical committee (Bayerische Landesa¨rztekammer). Indi-
viduals from both the discovery and replication sample were of Caucasian background to limit
biases resulting from ethnic disparities. Individuals from both the discovery and replication
samples were of Northern European background to limit genetic heterogeneity.
Two different analyses were conducted in the discovery sample. First, methylation levels
were compared in the full discovery sample, comprising 281 individuals. In addition, methyla-
tion status was compared in a subsample of 33 MZ twin pairs discordant for CWP. The study of
epigenetics and disease using discordant MZ twins offers the opportunity to control for many
potential confounders encountered in general population studies, such as differences in genetic
background, early-life environmental exposure, age, gender, and cohort effects. It therefore rep-
resents a more advantaegous model and offers more power using a smaller sample to detect
potential differences between disease-affected and non-affected individuals. The 20 most signifi-
cant loci from both analyses (the discordant MZ subsample and the full discovery sample) were
then carried forward for replication in the independent KORA sample (N = 1485).
CWP Phenotype
Different instruments were used in the replication and discovery cohort to assess and define
the main phenotype CWP. In the discovery sample, the London Fibromyalgia Epidemiology
Symptom Screening Questionnaire (LFESSQ) was used to screen for self-reported CWP [18].
Epigenetics of CWP
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This 6-item questionnaire was originally designed to screen for FM in the general population
and in specific patient groups and includes 4 items relating to widespread pain, and 2 items
relating to fatigue. For the assessment of CWP, the four items pertaining to the “pain subscale”
and asking about pain left and right of body and above and below diaphragm lasting at least 7
days in the previous 3 months were considered. In order to be classified as having CWP, par-
ticipants had to respond “yes” to all four pain items with either both a right- and left-side posi-
tive response or a positive response for pain at both sides. The utility of this phenotype
assessment is supported by the contribution these twins have made to previous studies, such as
the genome-wide association meta-analysis conducted by Peters and colleagues [7] or the twin
studies by Burri and colleagues [5].
In KORA S4, pain was assessed as part of a self-report questionnaire based on the question
“To what extent did pain hinder you in your daily tasks at home and at work during the past 4
weeks?,” for which the participants could select from following answers: “no pain” (0), “not at all”
(1), “slightly” (2), “moderately” (3), “quite” (4), “very” (5), “do not know.” The pain variable was
examined as a dichotomous variable, identifying controls (CWPq< 3) and cases (CWPq 3).
Illumina 450k DNA methylation analysis
Discovery Sample. Data and methylation analyses were conducted by common standard
procedures in the discovery and the replication sample. In the discovery sample, DNA methyl-
ation analyses were performed in the R environment (http://cran.r-project.org) using raw
intensity data files (IDAT files) as an input [19]. In all samples, the fraction of failed probes per
sample did not exceed a quality contol cut-off (< 0.05). Multi-dimensional scaling and hierar-
chical clustering analyses were used to assess samples for outliers and no outliers were identi-
fied. Probes exhibiting detection p-values >0.01 were excluded from further analysis.
Detection p-values predict whether the target probes signals are distinguishable from a set of
background probe. For statistical analysis M-values (log2-ratios of methylated and unmethy-
lated probes intensities) were used due to their presumed higher statistical validity [20]. Analy-
ses of DNA methylation in 33 MZ twin pairs who screened discordant for CWP were carried
out with the RnBeads package [21]. After removal of probes with detection p-values >0.01 in
any of the samples, 483,017 probes were retained. Normalization was performed using the
manufacturer-recommended scaling to internal controls as implemented in methylumi
(method = "illumina"). Background correction was carried out with the Lumi option also as
implemented in methylumi (bgcorr.method = "methylumi.lumi"). Paired-analysis of differen-
tial DNA methylation for the 33 MZ twin pairs was performed using paired Student’s t-test.
Age, array number, array position and processing batch were included as covariates in the
analysis. The false discovery rate (FDR) after correction for multiple testing was set to 0.05. A
priority-ranked list of differentially methylated CpGs was obtained, with rank based on a com-
bination of statistical significance and absolute and relative effect size. The reason to select a
rank approach in the discordant twin pairs analysis was to account also for effect sizes, which
were the commonly very small between discordant twins.
DNA methylation patterns were further compared in a sample of unpaired twin individu-
als. One twin from each twin pair was chosen randomly, resulting in a sample of N = 281 unre-
lated individuals, out of which 200 screened negative and 81 screened positive for CWP. The
data import, quality control and normalization steps of the minfi Bioconductor package were
used [22,23]. Probes with detection p-values >0.01 in any of the samples were removed. Nor-
malization and background correction were performed following the Illumina recommended
procedures (bg.correct = TRUE, normalize = "controls") Q-Q plots of observed versus expected
−log10 (p-values) in the unrelated CWP sample before and after normalization are shown in
Epigenetics of CWP
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Fig 1. Differential methylation between the CWP positively and negatively screened individuals
was estimated with the CpGassoc package [24]. Age, array number and array position were
included as covariates in the analysis and processing batch was included as a fixed effect. The
FDR (after Benjamini-Hochberg correction for multiple comparisons) was set at 0.05.
Replication Sample. In the replication sample, array-based DNA methylation data was
also measured using the Infinium HumanMethylation450 BeadChip Array. The bisulfite con-
version and genome-wide methylation assessment were performed as described in Zeilinger
et al. [25]. Normalization of the methylation data was conducted following the pipeline of
Lehne et al. [26] beginning with exclusion of 65 rs-probes (SNP probes) and background cor-
rection using the minfi R package. Probes were set to NA if the detection p-value was0.01or
if the number of beads was3. Samples were excluded if the detection rate was0.95. Quan-
tile normalization, as given by Lehne et al. [26] then resulted in intensity values used to calcu-
late the β-values. Following normalization, a site-by-site detection rate of 95% was applied to
the KORA S4 cohort. To eliminate technical effects, the final methylation values for each CpG
site were calculated as the residuals of a linear regression with the methylation value as
response and the 20 control probe principal components (PCs) as covariates. The control
probe PCs were calculated on all green and red intensities of all (non-negative, autosomal)
control probes together, after background correction. The linear model for methylation
(adjusted for the technical bias) and the binary CWP was estimated with the statistical software
R, using age and sex as covariates.
Database for Annotation, Visualization and Integration Discovery
(DAVID) analysis
Genes to which any of the top 20 differentially methylated CpG sites were annotated were
entered in the Database for Annotation, Visualization and Integration Discovery (DAVID), a
Fig 1. Q-Q plots in the unrelated UK sample. Before normalization (A) and after normalization (B) of the data.
doi:10.1371/journal.pone.0165548.g001
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high-throughput and integrated data-mining environment. Functional annotation clustering
was carried out and clusters with enrichment scores > 1.3 (a previously suggested threshold)
are reported [27].
Results
The full final discovery sample of unrelated female twins (N = 281) consisted of 81 (28.8%)
individuals having CWP (mean age ± SD was 62.7 ± 9.9 years). For the CWP-discordant MZ
analyses, 33 full MZ twin pairs were available (mean age ± SD for the twin pairs was
61.8 ± 10.7). The final replication sample consisted of N = 1535. The overall mean age of the
sample was 54.41 for men and 53.83 for women.
Differentially methylated positions in CWP discordant MZ twins
A SNP heatmap of the 65 genotyping probes on the Illumina Infinium Human Methylation
450 BeadChip which measures single nucleotide polymorphisms, was used to assess genotype-
related similarities between the samples. It showed clustering of each twin pair and no con-
vincing additional clusters among the subjects (Fig 2). A list of the top ranked 20 DMPs
between the CWP discordant twin pairs can be found in Table 1. Among the top 20 ranked
DMPs we identified one mapped to monoamine oxidase B (MAOB; p = 0.08)–a gene previ-
ously implicated in neuropathic and postoperative pain [28,29]. Functional annotation cluster-
ing (FAC) of genes with hypermethylated CpG sites in CWP-affected MZ twins using the
DAVID database further identified a cluster related to DNA binding, regulation of transcrip-
tion, nucleus as well as developmental proteins (Enrichment score 1.81, genes: BANP, NKX6-2,
T). FAC of genes with hypomethylated CpG sites in CWP-affected twins did not show any sig-
nificantly enriched clusters (Table 2).
Differentially methylated sites in unrelated twin individuals
To identify DMPs in individuals with CWP compared to healthy controls in the unrelated
sample, we fitted a fixed effects model regressing methylation levels at each probe on CWP
Fig 2. SNP Heatmap. A SNP heatmap of the 65 genotyping probes on the Illumina 450k array for the 33 CWP discordant monozygotic twin pairs.
doi:10.1371/journal.pone.0165548.g002
Epigenetics of CWP
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status of the individuals and included age, array number, and array position as covariates and
processing batch as a fixed effect. The top 20 DMPs between the two groups are presented in
Table 3. These 20 DMPs included CpG islands (50%); north shores (15%); south shores (10%);
as well as south shelves (5%) and sites that were not annotated into the previously noted cate-
gories (20%). Overall, the top 20 DMPs were localized around17 different genes (Table 3). The
highest statistical significance between the groups was found for cg11251499, which is anno-
tated to the 1st exon/50-UTR of RE1-silencing transcription factor (REST), named also neuron-
restrictive silencer factor (NRSF) (p-value 2.23 × 10−6)–a transcriptional repressor, which
represses the expression of neuronal genes in non-neuronal cells [30–32]. REST has previously
been implicated in pain perception [30]. Among the 20 most strongly associated DMRs,
another previously reported biological candidate for pain—collagen type I alpha 2 chain
(COL1A2)–could be detected. FAC of genes with hypomethylated or hypermethylated CpG
sites in CWP positively screened individuals in the unrelated sample did not show significant
enrichment.
Table 1. Top 20 differentially methylated CpG positions in monozygotic twins discordant for CWP (N = 66) from the TwinsUK discovery sample.
Included are CpG positions ranked on combination of p-values and Δβ. Within the table these positions are for consistensy arranged based on their p-values.
CpG site Chromosome p-value Δβ Gene
cg20114732 6 0.0006 -0.022 T
cg24847846 3 0.0021 0.04
cg06782035 5 0.0023 0.0997 March 11
cg04246144 5 0.0025 0.024 PCDHG
cg25485875 10 0.0028 -0.023 NKX6-2
cg08270148 8 0.0034 0.024 ERICH-AS1
cg07518837 8 0.0037 0.025 SPAG1
cg03341469 1 0.0037 0.029 YIPF1
cg05224642 16 0.0066 -0.063 BANP
cg14061270 5 0.0069 0.025
cg07258715 3 0.0077 0.024 TMEM40
cg03874092 2 0.0121 0.021 BCL11A
cg13749548 14 0.0125 0.063
cg21210232 1 0.0126 0.03 RNF207
cg00324979 16 0.0137 0.04
cg08629394 12 0.0158 0.021
cg03548123 19 0.0179 0.042
cg09357232 X 0.018 0.045 MAOB
cg17324941 10 0.0231 0.022 CDC10L
cg25173405 17 0.0256 0.028 ITGB3
Note: Δβ represents the difference of mean β levels of unaffected twins minus mean β levels of CWP-affected twins measured with pair-wise comparison
doi:10.1371/journal.pone.0165548.t001
Table 2. Functional annotation cluster analysis of hypermethylated genes in the CWP-affected MZ
twins from the TwinsUK sample (N = 33).
Annotation Cluster (Enrichment Score 1.81)
Term Genes p-value
Developmental protein BANP, NKX6-2, T 0.0016
DNA binding BANP, NKX6-2, T 0.032
Regulation of transcription BANP, NKX6-2, T 0.037
Nucleus BANP, NKX6-2, T 0.05
doi:10.1371/journal.pone.0165548.t002
Epigenetics of CWP
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Independent replication analyses of the 40 most strongly associated
DMRs
The same Infinium HumanMethylation450 BeadChip Array was used for the replication of in
an independent sample of n = 1485 individuals. Of these 40 DMRs, three reached EWAS sig-
nificance in the indepenedent replication analyses. The three CpGs reaching significant p-val-
ues in the replication sample were malate dehydrogenase 2 (MDH2; p-value 0.017), tetranectin
(CLEC3B; p-value 0.039), and heat shock protein beta-6 (HSPB6; p-value 0.016; Table 4). The
significant associations between the previously reported biological candidates for pain identi-
fied in the discovery cohort–including REST, MAOB, COL1A2—could not be successfully rep-
licated (Table 4).
Discussion
Several interesting candidates could be identified in our discovery analyses, including REST,
MAOB, COL1A2. Although none of these candidates were successfully replicated in our inde-
pendent replication sample, further investigation of these candidates is warranted given previ-
ous reports of their involvement and importance in pain regulation. Although small in
number, study findings in animal models and humans, for example, have repeatedly under-
lined the analgesic properties of reversible MAO-A inhibitors in the treatment of nociceptive
and psychogenic pain [33–35]. The majority of the evidence stems from pharmacological trials
investigating the therapeutic effects of MAO inhibitors on patients reporting different pain
disorders. Although they are not officially approved for this indication, antidepressants–
including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs),
and MAOIs—have been used in the treatment of FM. A study by Pillidar and colleagues [34],
for example, found moclobemide—a reversible inhibitor of monoamine oxidase type A—to be
Table 3. Top 20 differentially methylated CpG positions between unrelated individuals who screened positive (N = 81) or negative (N = 200) for
CWP from the TwinsUK discovery sample.
CpGsite Chromosome p-value Gene
cg11251499 4 0.00000223 REST
cg16116574 21 0.00000258 WRB
cg01832802 14 0.00000293
cg03528037 7 0.00000845 MDH2
cg17658717 3 0.00000917 CLEC3B
cg05709655 17 0.00000105 MRPL10
cg01828911 8 0.0000116 TMEM65
cg26122815 7 0.0000125
cg18274749 1 0.0000126 HSPG2
cg19439810 1 0.0000172 LRRC41
cg00727590 22 0.0000181 PLAG3
cg11721464 19 0.0000222 DEDD2
cg25121621 15 0.0000225 SQRDL
cg05368740 19 0.0000229 HSPB6
cg06547513 5 0.0000234 BOD1
cg09172260 1 0.0000262
cg08270148 8 0.000027 ERICH1-AS1
cg08068547 16 0.0000275 CLEC18C
cg06299997 7 0.0000277 COL1A2
cg21533667 11 0.0000293 TIRAP
doi:10.1371/journal.pone.0165548.t003
Epigenetics of CWP
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an effective option in the management of perceived pain, as well as of symptoms of somatiza-
tion. Similarly, a review by Tort and colleagues [36] suggested a moderate effect of MAOIs on
pain and a small effect on tender points. Supporting this conclusion, a meta-analysis con-
ducted by Ha¨user and colleagues found medium effect sizes for MAOIs for pain reduction
[37]. Further evidence for an involvement of MAO in pain comes from genetic studies, such as
Table 4. Replication of the 40 top hits of the TwinsUK discovery sample (using the discordant MZ subsample and the full unrelated twin invidiual
sample) in the KORA sample (n = 1485).
CpGsite Chromosome p-value beta Gene
cg01832802 14 0.01320211 -0.003432303
cg05368740 19 0.016262306 -0.010034953 HSPB6
cg03528037 7 0.017296535 -0.002337927 MDH2
cg17658717 3 0.039688442 0.009062029 CLEC3B
cg01828911 8 0.062226055 -0.001406351 TMEM65
cg08068547 16 0.110222159 -0.002210019 CLEC18C
cg13749548 14 0.110337895 0.035490098
cg03874092 2 0.131432182 -0.006618897 BCL11A
cg26122815 7 0.162250567 -0.000894128
cg03341469 1 0.176709411 0.005727599 YIPF1
cg03548123 19 0.196329334 -0.005465924
cg20114732 6 0.210104479 0.001951687 T
cg08629394 12 0.338996394 0.015834355
cg18274749 1 0.340404642 0.001334824 HSPG2
cg08270148 8 0.349516713 0.014808354 ERICH-AS1
cg08270148 8 0.349516713 0.014808354 ERICH1-AS1
cg19439810 1 0.361275045 -0.000813882 LRRC41
cg00727590 22 0.367093565 -0.001693948 PLAG3
cg17324941 10 0.368200397 0.005855138 CDC10L
cg05709655 17 0.371794037 0.000403952 MRPL10
cg11251499 4 0.384135807 -0.000632606 REST
cg11721464 19 0.410554495 0.000448264 DEDD2
cg06299997 7 0.420155271 -0.00498292 COL1A2
cg21533667 11 0.528052836 0.000200271 TIRAP
cg25121621 15 0.554768769 0.001318241 SQRDL
cg06547513 5 0.61388428 0.001285164 BOD1
cg09172260 1 0.625012034 -0.000801437
cg25485875 10 0.649094944 -0.000638613 NKX6-2
cg07258715 3 0.76278516 0.005259776 TMEM40
cg16116574 21 0.789771688 -0.000457843 WRB
cg04246144 5 0.808636173 0.000376645 PCDHG
cg21210232 1 0.810668502 -0.001111336 RNF207
cg09357232 X 0.81928154 0.000503532 MAOB
cg25173405 17 0.873513415 0.000803712 ITGB3
cg24847846 3 0.91253349 0.000633851
cg14061270 5 0.928871385 0.001535984
cg05224642 16 0.940751914 0.000230206 BANP
cg07518837 8 0.943457128 0.000302165 SPAG1
cg06782035 5 0.994893721 -1.30E-05 March 11
cg00324979 16 0.998919474 1.67E-05
doi:10.1371/journal.pone.0165548.t004
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the experimental study conducted by Treister et al. [38]. Using a Transmission Disequilibrium
Test (TDT) on 192 individuals, the authors found significant associations between cold pain
tolerance and MAO-A polymorphisms, suggesting an involvement of MAO in pain sensitivity.
Similarly, the significant associations between the A/G polymorphism of the MAOB gene and
postoperative pain intensity found by Sery et al., also point towards a potential role of MAOB
in the perception of pain intensity [28].
Results from our larger sample of unrelated individuals also revealed a high, albeit non-sig-
nificant, association between COL1A2 and CWP. The COL1A2 gene provides instructions for
the creation of type I collagen, which is known to strengthen and support many tissues in the
body (including cartilage, bone, tendon, skin, etc.). A number of previous studies have shown
a link between collagen and FM. The 27 female FM patients included in a muscle biopsy study
by Gronemann et al. [39], for example, showed significantly lower amount of intramuscular
collagen compared to healthy controls. The authors argued that the reduced collagen may
lower the threshold for muscle micro-injury and consequently resulting in non-specific signs
of muscle pathology. Further exploring the distribution and amount of collagen in skin from
non-tender-point areas in N = 27 female FM patients, Ribel-Madsen et al. detected differences
between the amino acid composition of skin proteins, i.e., fewer amount and less density, in
FM patients compared with controls [40]. Yet another study conducted on 20 FM patients
even found a marginal symptomatic improvement of chronic FM symptoms by taking colla-
gen hydrolysat–a prescription-free food supplement [41].
Functional annotation clustering of our CWP-discordant MZ results further revealed
enrichment in genes with hypermethylated CpGs in the CWP-affected twins for DNA binding,
regulation of transcription, nucleus as well as developmental proteins (i.e., BANP, NKX6-2).
These findings are in line with a previous study by Menzies and colleagues which identified
enrichment in differentially methylated sites to clusters involved in neuron differentiation,
development (nervous and skeletal/organ system) and chromatin compaction in women with
FM [11].
Of our 40 DMRs that were carried forward for replication, three CpGs reached significant
p-values in the replication sample and included MDH2, CLEC3B, and HSPB6. While, to the
best of our knowledge, none of them have previously been related to pain perception or
expression, a recent comparative analysis of gene expression in tendinopathy found evidence
of CLEC3B (and COL1A2) upregulation in tendon cells in response to cyclic strain [42]. Wide-
spread tenderness of muscles and the areas around tendon insertions (as well as increased
prevalence of tendinitis) is a common clinical presentation in patients with FM and CWP and
an involvement of CLEC3B in these musculoskeletal and connective tissue disorders is likely
[43].
Limitations
Several study limitations have to be considered such as the relatively small sample size of the
discovery sample, especially the subsample of discordant MZ twins. This might be one reason
why statistical significance at FDR< 0.05 was not reached. Furthermore, comorbidities such
as anxiety and depression were not taken into account, as this would have resulted in very low
statistical power. Due to the relatively high mean age of our sample, extrapolation of the
detected differences to other study populations is not necessarily possible. In the replication
and discovery cohort, different instruments were used to assess and define the main phenotype
CWP. This could be one reason why replication of the main findings fell short. However, we
believe that it can equally be seen as a strength rather than a weakness that we were able to par-
tially replicate our findings although phenotype assessment (and study population) were
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different. Furthermore, the different mean ages of the discovery and replication sample, as well as
the fact that the cohorts were of different cultural background (UK vs Germany)–albeit homoge-
nous in terms of ethnic background–could be other reasons why the main findings did not repli-
cate. Finally, we used blood samples for the detection of DNA methylation patterns. It is well
known that epigenetic patterns are tissue-specific, therefore the study of central and peripheral
nervous system tissues would be of great interest, but are very hard to obtain in humans [44].
Conclusion
In this large EWAS study of CWP we found evidence for the involvement of epigenetic factors.
These preliminary results serve as a starting point to encourage further replication in large and
independent population-based cohorts and subsequent biological investigation to elucidate
possible disease mechanisms. Ultimately, understanding the key mechanisms underlying
CWP may lead to new treatments and inform clinical practice and developments in psychiatric
nosology.
Supporting Information
S1 Fig. Differences in DNA methylation values (Δβ) of unaffected minus CWP-affected
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